Cargando…
Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine?
BACKGROUND: Using serum creatinine leads to an overestimation of kidney function in patients with primary neuromuscular disorders, and reduced kidney function may remain undetected. Cystatin C (CysC) could provide a better estimation. AIM: To evaluate the precision, accuracy, and bias of two creatin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926948/ https://www.ncbi.nlm.nih.gov/pubmed/34351595 http://dx.doi.org/10.1007/s40620-021-01122-x |
_version_ | 1784670340634378240 |
---|---|
author | Aldenbratt, Annika Lindberg, Christopher Johannesson, Elias Hammarsten, Ola Svensson, Maria K. |
author_facet | Aldenbratt, Annika Lindberg, Christopher Johannesson, Elias Hammarsten, Ola Svensson, Maria K. |
author_sort | Aldenbratt, Annika |
collection | PubMed |
description | BACKGROUND: Using serum creatinine leads to an overestimation of kidney function in patients with primary neuromuscular disorders, and reduced kidney function may remain undetected. Cystatin C (CysC) could provide a better estimation. AIM: To evaluate the precision, accuracy, and bias of two creatinine-, one cystatin C-based and one combined equation to estimate glomerular filtration rate (eGFR) in patients with primary neuromuscular disease. PATIENTS AND METHODS: Of the 418 patients initially identified at the out-patient clinic, data on kidney function was obtained for 145 adult patients (age 46 ± 14 years, BMI 26 ± 6 kg/m(2)) with primary neuromuscular disease. Kidney function was measured by iohexol clearance, and blood samples for serum creatinine and CysC were drawn simultaneously. Bias was defined as the mean difference between eGFR and measured iohexol clearance, and accuracy as the proportion of eGFRs within ± 10% (P10) of measured clearance. RESULTS: Kidney function (iohexol clearance) was 81 ± 19 (38–134) ml/min/1.73m(2). All equations overestimated kidney function by 22–60 ml/min/1.73m(2). eGFR CysC had the lowest bias overall 22 (95% CI 20–26) ml/min/1.73m(2) also at all levels of kidney function we evaluated (at 30–59 ml/min/1.73m(2) bias was 27 (95% CI 21–35), at 60–89 it was 25 (95% CI 20–28) and at ≥ 90 it was 12 (95% CI 7–22)). eGFR CysC also had the best accuracy in patients with reduced kidney function (P10 was 5.9% at 30–59 ml/min/1.73m(2)). CONCLUSIONS: Cystatin C-based estimations of kidney function performed better than creatinine-based ones in patients with primary neuromuscular disease, but most importantly, all evaluated equations overestimated kidney function, especially in patients with reduced kidney function. Therefore, kidney function should be measured by gold-standard methods when precision and accuracy are needed. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-021-01122-x. |
format | Online Article Text |
id | pubmed-8926948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89269482022-03-22 Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? Aldenbratt, Annika Lindberg, Christopher Johannesson, Elias Hammarsten, Ola Svensson, Maria K. J Nephrol Original Article BACKGROUND: Using serum creatinine leads to an overestimation of kidney function in patients with primary neuromuscular disorders, and reduced kidney function may remain undetected. Cystatin C (CysC) could provide a better estimation. AIM: To evaluate the precision, accuracy, and bias of two creatinine-, one cystatin C-based and one combined equation to estimate glomerular filtration rate (eGFR) in patients with primary neuromuscular disease. PATIENTS AND METHODS: Of the 418 patients initially identified at the out-patient clinic, data on kidney function was obtained for 145 adult patients (age 46 ± 14 years, BMI 26 ± 6 kg/m(2)) with primary neuromuscular disease. Kidney function was measured by iohexol clearance, and blood samples for serum creatinine and CysC were drawn simultaneously. Bias was defined as the mean difference between eGFR and measured iohexol clearance, and accuracy as the proportion of eGFRs within ± 10% (P10) of measured clearance. RESULTS: Kidney function (iohexol clearance) was 81 ± 19 (38–134) ml/min/1.73m(2). All equations overestimated kidney function by 22–60 ml/min/1.73m(2). eGFR CysC had the lowest bias overall 22 (95% CI 20–26) ml/min/1.73m(2) also at all levels of kidney function we evaluated (at 30–59 ml/min/1.73m(2) bias was 27 (95% CI 21–35), at 60–89 it was 25 (95% CI 20–28) and at ≥ 90 it was 12 (95% CI 7–22)). eGFR CysC also had the best accuracy in patients with reduced kidney function (P10 was 5.9% at 30–59 ml/min/1.73m(2)). CONCLUSIONS: Cystatin C-based estimations of kidney function performed better than creatinine-based ones in patients with primary neuromuscular disease, but most importantly, all evaluated equations overestimated kidney function, especially in patients with reduced kidney function. Therefore, kidney function should be measured by gold-standard methods when precision and accuracy are needed. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-021-01122-x. Springer International Publishing 2021-08-05 2022 /pmc/articles/PMC8926948/ /pubmed/34351595 http://dx.doi.org/10.1007/s40620-021-01122-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Aldenbratt, Annika Lindberg, Christopher Johannesson, Elias Hammarsten, Ola Svensson, Maria K. Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? |
title | Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? |
title_full | Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? |
title_fullStr | Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? |
title_full_unstemmed | Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? |
title_short | Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? |
title_sort | estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin c a better marker of kidney function than creatinine? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926948/ https://www.ncbi.nlm.nih.gov/pubmed/34351595 http://dx.doi.org/10.1007/s40620-021-01122-x |
work_keys_str_mv | AT aldenbrattannika estimationofkidneyfunctioninpatientswithprimaryneuromusculardiseasesisserumcystatincabettermarkerofkidneyfunctionthancreatinine AT lindbergchristopher estimationofkidneyfunctioninpatientswithprimaryneuromusculardiseasesisserumcystatincabettermarkerofkidneyfunctionthancreatinine AT johannessonelias estimationofkidneyfunctioninpatientswithprimaryneuromusculardiseasesisserumcystatincabettermarkerofkidneyfunctionthancreatinine AT hammarstenola estimationofkidneyfunctioninpatientswithprimaryneuromusculardiseasesisserumcystatincabettermarkerofkidneyfunctionthancreatinine AT svenssonmariak estimationofkidneyfunctioninpatientswithprimaryneuromusculardiseasesisserumcystatincabettermarkerofkidneyfunctionthancreatinine |